BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol 2019;4:781-93. [PMID: 31345778 DOI: 10.1016/S2468-1253(19)30184-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metab 2022;34:1700-18. [PMID: 36208625 DOI: 10.1016/j.cmet.2022.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Barcelos STA, Silva-Sperb AS, Moraes HA, Longo L, de Moura BC, Michalczuk MT, Uribe-Cruz C, Cerski CTS, da Silveira TR, Dall'Alba V, Álvares-da-Silva MR. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Ann Hepatol 2023;28:100769. [PMID: 36216309 DOI: 10.1016/j.aohep.2022.100769] [Reference Citation Analysis]
3 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
4 Gao F, Qiu X, Wang K, Shao C, Jin W, Zhang Z, Xu X. Targeting the Hepatic Microenvironment to Improve Ischemia/Reperfusion Injury: New Insights into the Immune and Metabolic Compartments. Aging Dis 2022;13:1196-214. [PMID: 35855339 DOI: 10.14336/AD.2022.0109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol 2022;28:425-72. [PMID: 35850495 DOI: 10.3350/cmh.2022.0186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang D, Wei X, Zhang Z, Chen X, Zhu R, Oh Y, Gu N. Tris (2-chloroethyl) phosphate (TCEP) induces obesity and hepatic steatosis via FXR-mediated lipid accumulation in mice: Long-term exposure as a potential risk for metabolic diseases. Chem Biol Interact 2022;:110027. [PMID: 35780845 DOI: 10.1016/j.cbi.2022.110027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol 2022;76:1379-91. [PMID: 35589257 DOI: 10.1016/j.jhep.2021.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
8 Ibrahim SH, Kamath BM, Loomes KM, Karpen SJ. Cholestatic liver diseases of genetic etiology: Advances and controversies. Hepatology 2022;75:1627-46. [PMID: 35229330 DOI: 10.1002/hep.32437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
9 Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022;43:1103-19. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
10 Gao W, Li Z, Chu H, Yuan H, Hu L, Yao L, Zhang L, Wang W, Lin R, Yang L. Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_6] [Reference Citation Analysis]
11 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 28.0] [Reference Citation Analysis]
12 Park JW, Kim SE, Lee NY, Kim JH, Jung JH, Jang MK, Park SH, Lee MS, Kim DJ, Kim HS, Suk KT. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. Int J Mol Sci 2021;23:426. [PMID: 35008852 DOI: 10.3390/ijms23010426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
13 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
14 Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep 2021;3:100346. [PMID: 34667947 DOI: 10.1016/j.jhepr.2021.100346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
15 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
16 Orozco-Aguilar J, Simon F, Cabello-Verrugio C. Redox-Dependent Effects in the Physiopathological Role of Bile Acids. Oxid Med Cell Longev 2021;2021:4847941. [PMID: 34527174 DOI: 10.1155/2021/4847941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 23.5] [Reference Citation Analysis]
18 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
19 Li J, Truong JK, Pachura K, Rao A, Gambeer S, Fuchs CD, Karpen SJ, Trauner M, Dawson PA. Active Enterohepatic Cycling is Not Required for the Choleretic Actions of 24-norUrsodeoxycholic Acid in Mice.. [DOI: 10.1101/2021.03.06.430841] [Reference Citation Analysis]
20 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
21 Wegermann K, Howe C, Henao R, Wang Y, Guy CD, Abdelmalek MF, Diehl AM, Moylan CA. Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:608-17. [PMID: 33860119 DOI: 10.1002/hep4.1665] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
23 Schattenberg JM. Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. Visc Med 2020;36:411-6. [PMID: 33251276 DOI: 10.1159/000507231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
25 Ampuero J, Romero-Gomez M. Stratification of patients in NASH clinical trials: A pitfall for trial success. JHEP Rep 2020;2:100148. [PMID: 32954243 DOI: 10.1016/j.jhepr.2020.100148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
26 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 29.0] [Reference Citation Analysis]
27 Zhu C, Claudel T, Trauner M. Bile Acids and Bilirubin in Liver Immunology. Liver Immunology 2020. [DOI: 10.1007/978-3-030-51709-0_7] [Reference Citation Analysis]
28 Chan WK, Wong VW. A new bile acid treatment for non-alcoholic fatty liver disease. The Lancet Gastroenterology & Hepatology 2019;4:747-9. [DOI: 10.1016/s2468-1253(19)30183-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]